Amgen's diverse portfolio ensures stability, but risks like high debt and biosimilar competition loom. Check out my look at ...

Sales of the company’s copycat to J&J’s blockbuster reached $150 million in the first quarter, adding to a surge in revenue ...

Q1 2025 Earnings Call Transcript May 1, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $4.9, expectations were ...

It’s been 19 months since Amgen completed its $27.8 billion acquisition of Horizon Therapeutics, and the California company ...

James Bradner; Executive Vice President, Research and Development, and Chief Scientific Officer; Amgen Inc Peter Griffith; Executive Vice President and Chief Financial Officer; Amgen Inc Good ...

Amgen AMGN reported first-quarter 2025 adjusted earnings of $4.90 per share, which beat the Zacks Consensus Estimate of $4.16 ...

US biotech major Amgen (Nasdaq AMGN) late Thursday announced financial results for the first quarter of 2025, revealing that ...

Amgen Inc (AMGN) reports a robust 9% revenue increase driven by key brands, despite facing pricing pressures and strategic ...

Amgen’s product sales are expected to have been driven by strong volume growth of products like Evenity, Repatha, Kyprolis ...

As global stock markets experience significant fluctuations in April 2025 due to world trade conflicts, more investors are seeking refuge in stable, dividend-paying stocks. The S& ...

The FDA has approved Uplizna (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease in adult patients.

adding to Amgen Inc. (NASDAQ:AMGN)’s strong rare illness portfolio. With the introduction of new indications for UPLIZNA, a treatment for neuromyelitis optica spectrum disorder (NMOSD), the ...